Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: The ERMETIC study part 3

I. Borget; J. Cadranel; J. P. Pignon; E. Quoix; B. Coudert; V. Westeel; E. Dansin; J. Madelaine; A. Madroszyk; S. Friard; C. Daniel; F. Morin; C. Chouaid; V. Gounant; A. Lavole; B. Milleron; M. Wislez; M. Antoine; V. Poulot; P. Cervera; N. Hoyeau-Idrissi; M. Baud; M. Febvre; C. Danel; E. Fabre-Guillevin; J. Médioni; M. Riquet; H. Blons; F. Coulet; B. Besse; J. M. Bidart; J. Bosq; P. Fouret; L. Lacroix; J. C. Soria; G. Danton; A. Maugen; E. Rolland; P. Saulnier; S. Michiels; J. Chasles; F. Galateau-Salle; R. Gervais; A. Hardouin; M. L. Kottler; S. Lecot-Cotigny; H. Mittre; A. Rivière; G. Zalcman; N. Richard; C. Brambilla; E. Brambilla; S. Dufort; M. C. Favrot; S. Lantuejoul; D. Moro-Sibilot; F. De Praipont; F. Clément; P. E. Falcoz; P. Jacoulet; M. Gainet; C. Mougin; E. Ranfaing; J. L. Pretet; M. Carrère; A. Chapelier; P. De Cremoux; M. Laë; C. Luco; X. Sastre-Garau; A. Degeorges; M. P. Chenard; M. P. Gaub; B. Mennecier; A. Neuville; P. Oudet; A. M. Ruppert; M. Beau-Faller; B. Chetaille; A. Goncalves; I. Madroszyk; V. Rémy; P. Viens; L. Xerri; S. Olschwang; M. C. Copin; J. J. Lafitte; A. Lansiaux; Y. M. Robin; A. Scherpereel; M. P. Buisine; L. Arnould; A. Bernard; A. Fanton; P. Foucher; F. Piard; S. Lizard; H. Doubre; E. Longchampt; C. Andrieu; R. Lidereau; I. Bieche; H. Chapuis; E. Coste; M. Taulelle; V. Vidal; J. C. Boyer; J. Hureaux; Y. Le Guen; Y. Malthiery; P. Reynier; M. C. Rousselet-Chapeau; F. Savagner; T. Urban; D. Prunier-Mirebeau; M. Mounawar; P. Hainaut

doi:10.1183/09031936.00201210

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: The ERMETIC study part 3

I. Borget, J. Cadranel, J. P. Pignon, E. Quoix, B. Coudert, V. Westeel, E. Dansin, J. Madelaine, A. Madroszyk, S. Friard, C. Daniel, F. Morin, C. Chouaid, V. Gounant, A. Lavole, B. Milleron, M. Wislez, M. Antoine, V. Poulot, P. CerveraN. Hoyeau-Idrissi, M. Baud, M. Febvre, C. Danel, E. Fabre-Guillevin, J. Médioni, M. Riquet, H. Blons, F. Coulet, B. Besse, J. M. Bidart, J. Bosq, P. Fouret, L. Lacroix, J. C. Soria, G. Danton, A. Maugen, E. Rolland, P. Saulnier, S. Michiels, J. Chasles, F. Galateau-Salle, R. Gervais, A. Hardouin, M. L. Kottler, S. Lecot-Cotigny, H. Mittre, A. Rivière, G. Zalcman, N. Richard, C. Brambilla, E. Brambilla, S. Dufort, M. C. Favrot, S. Lantuejoul, D. Moro-Sibilot, F. De Praipont, F. Clément, P. E. Falcoz, P. Jacoulet, M. Gainet, C. Mougin, E. Ranfaing, J. L. Pretet, M. Carrère, A. Chapelier, P. De Cremoux, M. Laë, C. Luco, X. Sastre-Garau, A. Degeorges, M. P. Chenard, M. P. Gaub, B. Mennecier, A. Neuville, P. Oudet, A. M. Ruppert, M. Beau-Faller, B. Chetaille, A. Goncalves, I. Madroszyk, V. Rémy, P. Viens, L. Xerri, S. Olschwang, M. C. Copin, J. J. Lafitte, A. Lansiaux, Y. M. Robin, A. Scherpereel, M. P. Buisine, L. Arnould, A. Bernard, A. Fanton, P. Foucher, F. Piard, S. Lizard, H. Doubre, E. Longchampt, C. Andrieu, R. Lidereau, I. Bieche, H. Chapuis, E. Coste, M. Taulelle, V. Vidal, J. C. Boyer, J. Hureaux, Y. Le Guen, Y. Malthiery, P. Reynier, M. C. Rousselet-Chapeau, F. Savagner, T. Urban, D. Prunier-Mirebeau, M. Mounawar, P. Hainaut

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

37 Citations (Scopus)

Résumé

Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not been evaluated. The objective of this study was to compare the incremental costeffectiveness ratios of strategies for second-line erlotinib initiation in NSCLC: clinically guided initiation (nonsmoking females with adenocarcinoma received erlotinib; all other patients received docetaxel) and biologically guided selection (patients with epidermal growth factor receptor (EGFR) mutation received erlotinib; patients with wild-type EGFR or unknown status received docetaxel), compared with initiation with no patient selection (strategy reference). A Markov model was constructed. Outcomes (overall and progression-free survival), transition probabilities and direct medical costs (from the French third-party payer's perspective) were prospectively collected for individual patients treated with either erlotinib or docetaxel, from treatment initiation to disease progression. Published data were used to estimate utilities and post-progression costs. Sensitivity analyses were performed. The biologically and clinically guided strategies were both more efficient (incremental quality-adjusted life-yrs equal to 0.080 and 0.081, respectively) and less expensive (cost decrease equal to €5,020 and €5,815, respectively) than the no-selection strategy, and the biologically guided strategy was slightly less expensive than the clinically guided strategy. Sensitivity analyses confirmed the robustness of the results. The cost-effectiveness of second-line NSCLC treatment is improved when patients are selected on either clinical or biological grounds.

langue originale	Anglais
Pages (de - à)	172-179
Nombre de pages	8
journal	European Respiratory Journal
Volume	39
Numéro de publication	1
Les DOIs	https://doi.org/10.1183/09031936.00201210
état	Publié - 1 janv. 2012

Accès au document

10.1183/09031936.00201210

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Borget, I., Cadranel, J., Pignon, J. P., Quoix, E., Coudert, B., Westeel, V., Dansin, E., Madelaine, J., Madroszyk, A., Friard, S., Daniel, C., Morin, F., Chouaid, C., Gounant, V., Lavole, A., Milleron, B., Wislez, M., Antoine, M., Poulot, V., ... Hainaut, P. (2012). Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: The ERMETIC study part 3. European Respiratory Journal, 39(1), 172-179. https://doi.org/10.1183/09031936.00201210

@article{cc5d2d9794f944e0987364ed17051158,

title = "Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: The ERMETIC study part 3",

abstract = "Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not been evaluated. The objective of this study was to compare the incremental costeffectiveness ratios of strategies for second-line erlotinib initiation in NSCLC: clinically guided initiation (nonsmoking females with adenocarcinoma received erlotinib; all other patients received docetaxel) and biologically guided selection (patients with epidermal growth factor receptor (EGFR) mutation received erlotinib; patients with wild-type EGFR or unknown status received docetaxel), compared with initiation with no patient selection (strategy reference). A Markov model was constructed. Outcomes (overall and progression-free survival), transition probabilities and direct medical costs (from the French third-party payer's perspective) were prospectively collected for individual patients treated with either erlotinib or docetaxel, from treatment initiation to disease progression. Published data were used to estimate utilities and post-progression costs. Sensitivity analyses were performed. The biologically and clinically guided strategies were both more efficient (incremental quality-adjusted life-yrs equal to 0.080 and 0.081, respectively) and less expensive (cost decrease equal to €5,020 and €5,815, respectively) than the no-selection strategy, and the biologically guided strategy was slightly less expensive than the clinically guided strategy. Sensitivity analyses confirmed the robustness of the results. The cost-effectiveness of second-line NSCLC treatment is improved when patients are selected on either clinical or biological grounds.",

keywords = "Cost-utility, EGFR mutation, Erlotinib, Nonsmall cell lung cancer",

author = "I. Borget and J. Cadranel and Pignon, {J. P.} and E. Quoix and B. Coudert and V. Westeel and E. Dansin and J. Madelaine and A. Madroszyk and S. Friard and C. Daniel and F. Morin and C. Chouaid and V. Gounant and A. Lavole and B. Milleron and M. Wislez and M. Antoine and V. Poulot and P. Cervera and N. Hoyeau-Idrissi and M. Baud and M. Febvre and C. Danel and E. Fabre-Guillevin and J. M{\'e}dioni and M. Riquet and H. Blons and F. Coulet and B. Besse and Bidart, {J. M.} and J. Bosq and P. Fouret and L. Lacroix and Soria, {J. C.} and G. Danton and A. Maugen and E. Rolland and P. Saulnier and S. Michiels and J. Chasles and F. Galateau-Salle and R. Gervais and A. Hardouin and Kottler, {M. L.} and S. Lecot-Cotigny and H. Mittre and A. Rivi{\`e}re and G. Zalcman and N. Richard and C. Brambilla and E. Brambilla and S. Dufort and Favrot, {M. C.} and S. Lantuejoul and D. Moro-Sibilot and {De Praipont}, F. and F. Cl{\'e}ment and Falcoz, {P. E.} and P. Jacoulet and M. Gainet and C. Mougin and E. Ranfaing and Pretet, {J. L.} and M. Carr{\`e}re and A. Chapelier and {De Cremoux}, P. and M. La{\"e} and C. Luco and X. Sastre-Garau and A. Degeorges and Chenard, {M. P.} and Gaub, {M. P.} and B. Mennecier and A. Neuville and P. Oudet and Ruppert, {A. M.} and M. Beau-Faller and B. Chetaille and A. Goncalves and I. Madroszyk and V. R{\'e}my and P. Viens and L. Xerri and S. Olschwang and Copin, {M. C.} and Lafitte, {J. J.} and A. Lansiaux and Robin, {Y. M.} and A. Scherpereel and Buisine, {M. P.} and L. Arnould and A. Bernard and A. Fanton and P. Foucher and F. Piard and S. Lizard and H. Doubre and E. Longchampt and C. Andrieu and R. Lidereau and I. Bieche and H. Chapuis and E. Coste and M. Taulelle and V. Vidal and Boyer, {J. C.} and J. Hureaux and {Le Guen}, Y. and Y. Malthiery and P. Reynier and Rousselet-Chapeau, {M. C.} and F. Savagner and T. Urban and D. Prunier-Mirebeau and M. Mounawar and P. Hainaut",

year = "2012",

month = jan,

day = "1",

doi = "10.1183/09031936.00201210",

language = "English",

volume = "39",

pages = "172--179",

journal = "European Respiratory Journal",

issn = "0903-1936",

number = "1",

}

Borget, I, Cadranel, J, Pignon, JP, Quoix, E, Coudert, B, Westeel, V, Dansin, E, Madelaine, J, Madroszyk, A, Friard, S, Daniel, C, Morin, F, Chouaid, C, Gounant, V, Lavole, A, Milleron, B, Wislez, M, Antoine, M, Poulot, V, Cervera, P, Hoyeau-Idrissi, N, Baud, M, Febvre, M, Danel, C, Fabre-Guillevin, E, Médioni, J, Riquet, M, Blons, H, Coulet, F, Besse, B, Bidart, JM, Bosq, J, Fouret, P, Lacroix, L, Soria, JC, Danton, G, Maugen, A, Rolland, E, Saulnier, P, Michiels, S, Chasles, J, Galateau-Salle, F, Gervais, R, Hardouin, A, Kottler, ML, Lecot-Cotigny, S, Mittre, H, Rivière, A, Zalcman, G, Richard, N, Brambilla, C, Brambilla, E, Dufort, S, Favrot, MC, Lantuejoul, S, Moro-Sibilot, D, De Praipont, F, Clément, F, Falcoz, PE, Jacoulet, P, Gainet, M, Mougin, C, Ranfaing, E, Pretet, JL, Carrère, M, Chapelier, A, De Cremoux, P, Laë, M, Luco, C, Sastre-Garau, X, Degeorges, A, Chenard, MP, Gaub, MP, Mennecier, B, Neuville, A, Oudet, P, Ruppert, AM, Beau-Faller, M, Chetaille, B, Goncalves, A, Madroszyk, I, Rémy, V, Viens, P, Xerri, L, Olschwang, S, Copin, MC, Lafitte, JJ, Lansiaux, A, Robin, YM, Scherpereel, A, Buisine, MP, Arnould, L, Bernard, A, Fanton, A, Foucher, P, Piard, F, Lizard, S, Doubre, H, Longchampt, E, Andrieu, C, Lidereau, R, Bieche, I, Chapuis, H, Coste, E, Taulelle, M, Vidal, V, Boyer, JC, Hureaux, J, Le Guen, Y, Malthiery, Y, Reynier, P, Rousselet-Chapeau, MC, Savagner, F, Urban, T, Prunier-Mirebeau, D, Mounawar, M & Hainaut, P 2012, 'Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: The ERMETIC study part 3', European Respiratory Journal, VOL. 39, Numéro 1, p. 172-179. https://doi.org/10.1183/09031936.00201210

TY - JOUR

T1 - Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer

T2 - The ERMETIC study part 3

AU - Borget, I.

AU - Cadranel, J.

AU - Pignon, J. P.

AU - Quoix, E.

AU - Coudert, B.

AU - Westeel, V.

AU - Dansin, E.

AU - Madelaine, J.

AU - Madroszyk, A.

AU - Friard, S.

AU - Daniel, C.

AU - Morin, F.

AU - Chouaid, C.

AU - Gounant, V.

AU - Lavole, A.

AU - Milleron, B.

AU - Wislez, M.

AU - Antoine, M.

AU - Poulot, V.

AU - Cervera, P.

AU - Hoyeau-Idrissi, N.

AU - Baud, M.

AU - Febvre, M.

AU - Danel, C.

AU - Fabre-Guillevin, E.

AU - Médioni, J.

AU - Riquet, M.

AU - Blons, H.

AU - Coulet, F.

AU - Besse, B.

AU - Bidart, J. M.

AU - Bosq, J.

AU - Fouret, P.

AU - Lacroix, L.

AU - Soria, J. C.

AU - Danton, G.

AU - Maugen, A.

AU - Rolland, E.

AU - Saulnier, P.

AU - Michiels, S.

AU - Chasles, J.

AU - Galateau-Salle, F.

AU - Gervais, R.

AU - Hardouin, A.

AU - Kottler, M. L.

AU - Lecot-Cotigny, S.

AU - Mittre, H.

AU - Rivière, A.

AU - Zalcman, G.

AU - Richard, N.

AU - Brambilla, C.

AU - Brambilla, E.

AU - Dufort, S.

AU - Favrot, M. C.

AU - Lantuejoul, S.

AU - Moro-Sibilot, D.

AU - De Praipont, F.

AU - Clément, F.

AU - Falcoz, P. E.

AU - Jacoulet, P.

AU - Gainet, M.

AU - Mougin, C.

AU - Ranfaing, E.

AU - Pretet, J. L.

AU - Carrère, M.

AU - Chapelier, A.

AU - De Cremoux, P.

AU - Laë, M.

AU - Luco, C.

AU - Sastre-Garau, X.

AU - Degeorges, A.

AU - Chenard, M. P.

AU - Gaub, M. P.

AU - Mennecier, B.

AU - Neuville, A.

AU - Oudet, P.

AU - Ruppert, A. M.

AU - Beau-Faller, M.

AU - Chetaille, B.

AU - Goncalves, A.

AU - Madroszyk, I.

AU - Rémy, V.

AU - Viens, P.

AU - Xerri, L.

AU - Olschwang, S.

AU - Copin, M. C.

AU - Lafitte, J. J.

AU - Lansiaux, A.

AU - Robin, Y. M.

AU - Scherpereel, A.

AU - Buisine, M. P.

AU - Arnould, L.

AU - Bernard, A.

AU - Fanton, A.

AU - Foucher, P.

AU - Piard, F.

AU - Lizard, S.

AU - Doubre, H.

AU - Longchampt, E.

AU - Andrieu, C.

AU - Lidereau, R.

AU - Bieche, I.

AU - Chapuis, H.

AU - Coste, E.

AU - Taulelle, M.

AU - Vidal, V.

AU - Boyer, J. C.

AU - Hureaux, J.

AU - Le Guen, Y.

AU - Malthiery, Y.

AU - Reynier, P.

AU - Rousselet-Chapeau, M. C.

AU - Savagner, F.

AU - Urban, T.

AU - Prunier-Mirebeau, D.

AU - Mounawar, M.

AU - Hainaut, P.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not been evaluated. The objective of this study was to compare the incremental costeffectiveness ratios of strategies for second-line erlotinib initiation in NSCLC: clinically guided initiation (nonsmoking females with adenocarcinoma received erlotinib; all other patients received docetaxel) and biologically guided selection (patients with epidermal growth factor receptor (EGFR) mutation received erlotinib; patients with wild-type EGFR or unknown status received docetaxel), compared with initiation with no patient selection (strategy reference). A Markov model was constructed. Outcomes (overall and progression-free survival), transition probabilities and direct medical costs (from the French third-party payer's perspective) were prospectively collected for individual patients treated with either erlotinib or docetaxel, from treatment initiation to disease progression. Published data were used to estimate utilities and post-progression costs. Sensitivity analyses were performed. The biologically and clinically guided strategies were both more efficient (incremental quality-adjusted life-yrs equal to 0.080 and 0.081, respectively) and less expensive (cost decrease equal to €5,020 and €5,815, respectively) than the no-selection strategy, and the biologically guided strategy was slightly less expensive than the clinically guided strategy. Sensitivity analyses confirmed the robustness of the results. The cost-effectiveness of second-line NSCLC treatment is improved when patients are selected on either clinical or biological grounds.

AB - Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not been evaluated. The objective of this study was to compare the incremental costeffectiveness ratios of strategies for second-line erlotinib initiation in NSCLC: clinically guided initiation (nonsmoking females with adenocarcinoma received erlotinib; all other patients received docetaxel) and biologically guided selection (patients with epidermal growth factor receptor (EGFR) mutation received erlotinib; patients with wild-type EGFR or unknown status received docetaxel), compared with initiation with no patient selection (strategy reference). A Markov model was constructed. Outcomes (overall and progression-free survival), transition probabilities and direct medical costs (from the French third-party payer's perspective) were prospectively collected for individual patients treated with either erlotinib or docetaxel, from treatment initiation to disease progression. Published data were used to estimate utilities and post-progression costs. Sensitivity analyses were performed. The biologically and clinically guided strategies were both more efficient (incremental quality-adjusted life-yrs equal to 0.080 and 0.081, respectively) and less expensive (cost decrease equal to €5,020 and €5,815, respectively) than the no-selection strategy, and the biologically guided strategy was slightly less expensive than the clinically guided strategy. Sensitivity analyses confirmed the robustness of the results. The cost-effectiveness of second-line NSCLC treatment is improved when patients are selected on either clinical or biological grounds.

KW - Cost-utility

KW - EGFR mutation

KW - Erlotinib

KW - Nonsmall cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84855398524&partnerID=8YFLogxK

U2 - 10.1183/09031936.00201210

DO - 10.1183/09031936.00201210

M3 - Article

C2 - 21659409

AN - SCOPUS:84855398524

SN - 0903-1936

VL - 39

SP - 172

EP - 179

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 1

ER -